Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

PURPOSE: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bortezomib, has improved pharmacokinetics, pharmacodyn...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Lee, Edmund C., Fitzgerald, Michael, Bannerman, Bret, Donelan, Jill, Bano, Kristen, Terkelsen, Jennifer, Bradley, Daniel P., Subakan, Ozlem, Silva, Matthew D., Liu, Ray, Pickard, Michael, Li, Zhi, Tayber, Olga, Li, Ping, Hales, Paul, Carsillo, Mary, Neppalli, Vishala T., Berger, Allison J., Kupperman, Erik, Manfredi, Mark, Bolen, Joseph B., Van Ness, Brian, Janz, Siegfried
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3443972/
https://ncbi.nlm.nih.gov/pubmed/21903769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0636
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια